文献速递急性肾损伤慢性肾脏病

蔗糖铁(RBT-3)激活肝与肾HAMP1基因,诱导肾脏铁调素负载并抵抗顺铂肾毒性

Iron sucrose ('RBT-3') activates the hepatic and renal HAMP1 gene, evoking renal hepcidin loading and resistance to cisplatin nephrotoxicity.
PubMed 文献 · Nephrol Dial Transplant · 2021-01-01

本研究在健康志愿者和CKD 3-4期患者中证实,新型蔗糖铁制剂RBT-3可快速、剂量依赖性地升高血浆铁调素(约15倍基线),并增加尿铁调素排泄。小鼠实验显示RBT-3主要上调肾脏HAMP1表达(>25倍),激活肾脏Nrf2通路,预适应18小时后显著减轻顺铂肾毒性(BUN/肌酐下降约50%),部分通过减少肾脏顺铂摄取(40%)实现。

要点

  • RBT-3在健康人和CKD患者中均快速升高血浆铁调素,24小时内达基线约15倍。
  • RBT-3主要上调肾脏而非肝脏HAMP1表达,并激活肾脏Nrf2抗氧化通路。
  • RBT-3预适应通过减少肾脏顺铂摄取(40%)等多机制减轻顺铂肾毒性。

核心结论

  • RBT-3急性显著上调保护性铁调素生成,增加肾脏铁调素水平。
  • RBT-3还激活Nrf2通路并减少顺铂摄取,多种细胞保护机制共同介导肾脏对顺铂的抵抗。

研究设计与样本

  • 健康志愿者(n=9)和CKD 3-4期患者(n=9)接受RBT-3 120、240或360 mg静脉输注2小时。
  • 补充小鼠实验比较RBT-3对肝与肾HAMP1 mRNA及蛋白水平的影响,并评估Nrf2通路和顺铂肾毒性。
  • 体外实验使用HK-2细胞测试外源性铁调素对顺铂毒性的直接作用。

主要发现

  • RBT-3诱导健康人和CKD患者血浆铁调素快速、剂量依赖性升高,24小时内约15倍基线。
  • 尿铁调素增加4倍,证实人肾脏铁调素暴露增加。
  • 小鼠肾脏HAMP1 mRNA上调>25倍,肝脏仅约2倍。
  • RBT-3激活肾脏Nrf2(核结合增加及下游基因mRNA升高:HO-1、Sulfiredoxin-1、GCLC、NQO1)。
  • RBT-3预适应(间隔18小时)使实验性顺铂肾毒性显著减轻(BUN/肌酐下降约50%),部分通过减少肾脏顺铂摄取40%。

关键数值与推荐

  • 健康志愿者和CKD 3-4期患者接受RBT-3 120、240或360 mg静脉输注2小时。
  • 血浆和尿铁调素于注射后0-72小时采集检测。
  • 小鼠RBT-3预适应18小时后评估顺铂肾毒性。

临床怎么用

  • RBT-3可能作为肾预适应策略,用于减轻顺铂相关急性肾损伤。
  • 需进一步临床研究验证RBT-3在顺铂化疗患者中的肾脏保护作用及最佳剂量。

局限性

  • 人类研究样本量小(每组n=9),未评估临床肾脏保护终点。
  • 顺铂肾毒性保护证据主要来自小鼠模型,外源性铁调素体外未显示保护作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Iron sucrose (FeS) administration induces a state of renal preconditioning, protecting against selected forms of acute kidney injury (AKI). Recent evidence suggests that recombinant hepcidin also mitigates acute renal damage. Hence the goals of this study were to determine whether a new proprietary FeS formulation ('RBT-3') can acutely activate the hepcidin (HAMP1) gene in humans, raising plasma and renal hepcidin concentrations; assess whether the kidney participates in this posited RBT-3-hepcidin generation response; test whether RBT-3 can mitigate a clinically relevant AKI model (experimental cisplatin toxicity) and explore whether mechanisms in addition to hepcidin generation are operative in RBT-3's cytoprotective effects. METHODS: Healthy human volunteers (n = 9) and subjects with Stages 3-4 CKD (n = 9) received 120, 240 or 360 mg of RBT-3 (intravenously over 2 h). Plasma and urine samples were collected and assayed for hepcidin levels (0-72 h post-RBT-3 injection). In complementary mouse experiments, RBT-3 effects on hepatic versus renal hepcidin (HAMP1) messenger RNA (mRNA) and protein levels were compared. RBT-3's impact on the mouse Nrf2 pathway and on experimental cisplatin nephrotoxicity was assessed. Direct effects of exogenous hepcidin on in vivo and in vitro (HK-2 cells) cisplatin toxicity were also tested. RESULTS: RBT-3 induced rapid, dose-dependent and comparable plasma hepcidin increases in both healthy volunteers and chronic kidney disease subjects (∼15 times baseline within 24 h). Human kidney hepcidin exposure was confirmed by 4-fold urinary hepcidin increases. RBT-3 up-regulated mouse hepcidin mRNA, but much more so in kidney (>25 times) versus liver (∼2 times). RBT-3 also activated kidney Nrf2 [increased Nrf2 nuclear binding; increased Nrf2-responsive gene mRNAs: heme oxygenase-1, sulfiredoxin-1, glutamate-cysteine ligase catalytic subunit and NAD(P)H quinone dehydrogenase 1]. RBT-3 preconditioning (18 h time lapse) markedly attenuated experimental cisplatin nephrotoxicity (∼50% blood urea nitrogen/creatinine decrements), in part by reducing renal cisplatin uptake by 40%. Exogenous hepcidin (without RBT-3) treatment conferred protection against mild in vivo (but not in vitro) cisplatin toxicity. CONCLUSIONS: RBT-3 acutely and dramatically up-regulates cytoprotective hepcidin production, increasing renal hepcidin levels. However, additional cytoprotective mechanisms are activated by RBT-3 (e.g. Nrf2 activation; reduced cisplatin uptake). Thus RBT-3-induced preconditioning likely confers renal resistance to cisplatin via an interplay of multiple cytoprotective activities.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Zager RA, Johnson ACM, Therapeutics R, et al. Iron sucrose ('RBT-3') activates the hepatic and renal HAMP1 gene, evoking renal hepcidin loading and resistance to cisplatin nephrotoxicity. Nephrol Dial Transplant. 2021. PMID: 33547792. doi:10.1093/ndt/gfaa348

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。